Champions Oncology reported first-quarter fiscal 2027 results ending July 31, 2026. Revenue increased 8.8% year-over-year to $15.2 million, driven by higher core research services and data license revenue. The oncology services margin improved significantly to 51% from 43% in the prior-year period, while Adjusted EBITDA rose to $671,000 from $59,000. The company reported a net loss of $426,000 compared to a $466,000 loss previously. Operating expenses increased by 7.7% to $15.6 million due to investments in the commercial organization and R&D. Cash and cash equivalents stood at approximately $4.4 million with no debt. Champions Oncology operates as a global preclinical and clinical research services provider specializing in oncology drug discovery.

Champions Oncology, Inc. reported record annual revenue of $59.4 million for the fiscal year ended April 30, 2026, a 4% increase over the prior year. The company achieved positive Adjusted EBITDA in all four quarters of FY 2026, with annual Adjusted EBITDA of $1.6 million. Despite record revenue, the company reported a GAAP loss from operations of $1.1 million for the year, compared to income of $4.6 million in FY 2025, primarily due to the absence of non-recurring data license revenue and increased investments in radiopharmaceuticals and its commercial organization. The company ended the period with $4.9 million in cash and no debt. Champions Oncology is a global preclinical and clinical research services provider offering oncology R&D solutions and data platforms to biopharma organizations.